Supernus to Present at March Cowen Health Care Conference

ROCKVILLE, Md., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the Cowen & Company 36th Annual Health Care Conference.

Date: Monday, March 7, 2016Time: 2:40 p.m. ETPlace: The Boston Marriott Copley Place, Boston, MA

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD. SPN-812 is being developed for treatment of ADHD.

CONTACT:

Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

Or

Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]

Source: Supernus Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BuyCryptoPressRelease.com Launches Specialized Crypto Press Release Distribution Platform for Blockchain and Web3 Projects 
• WISeKey Reports Unaudited Preliminary H1 2026 Key Metrics; Revenue Up 115%, FY 2026 Guidance Reaffirmed
• ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE